Read twice and referred to the Committee on Finance.
This bill (No Big Blockbuster Bailouts Act) amends the Medicare Drug Price Negotiation provisions in title XI of the Social Security Act to change how orphan drugs (drugs designated for rare diseases or conditions) are treated for purposes of inclusion in the Medicare negotiation program. The statutory change substitutes one numeric sales threshold for another in the provision that determines whether an orphan drug is treated under the program.
Whether the threshold change is an appropriate way to stop 'gaming' versus an overbroad policy that threatens innovation.
Relative to its intended legislative type, this bill is a narrowly targeted statutory amendment that identifies the specific provisions to change and sets an effective date.
This bill (No Big Blockbuster Bailouts Act) amends the Medicare Drug Price Negotiation provisions in title XI of the Social Security Act to change how orphan drugs (drugs designated for rare diseases or conditions) are treated for purposes of inclusion in the Medicare negotiation program.
The statutory change substitutes one numeric sales threshold for another in the provision that determines whether an orphan drug is treated under the program.
The amendments apply to initial price applicability years beginning on or after January 1, 2028.
On content alone the bill is a narrow, easily described statutory tweak that protects a focused category (orphan drugs) and therefore can attract targeted stakeholder support. However, because it affects federal drug price negotiation — a high‑stakes, politically sensitive policy area with clear fiscal implications — it is less likely to advance as a freestanding bill. Its best path would be inclusion as a provision in larger, negotiated drug‑pricing or budget legislation; absent that vehicle or clear offsets, the standalone probability of enactment is modest.
Relative to its intended legislative type, this bill is a narrowly targeted statutory amendment that identifies the specific provisions to change and sets an effective date. It is explicit in placement within existing law but lacks fiscal acknowledgement, detailed administrative instructions, and accountability safeguards. Portions of the amendment text in the provided copy appear garbled, which undermines clarity about the precise substitution intended.
Whether the threshold change is an appropriate way to stop 'gaming' versus an overbroad policy that threatens innovation.
These are examples from the analysis, not a ranked list of the most-affected groups.
Whether the threshold change is an appropriate way to stop 'gaming' versus an overbroad policy that threatens innovation.
A mainstream liberal would likely view the bill as a targeted fix to close a loophole that lets high-revenue orphan drugs avoid Medicare negotiation.
They would see it as strengthening the government's ability to negotiate lower drug prices and limiting so-called 'blockbuster' revenues that can be sheltered by orphan designations.
They would still be attentive to possible effects on incentives for rare-disease research and would want safeguards to protect truly small-market therapies.
A moderate would view this as a narrowly focused technical change to the Medicare negotiation statute intended to limit a perceived loophole, and would weigh potential savings and fairness gains against the risk of reducing incentives for rare-disease innovation.
They would want empirical analysis, a clear explanation of which numeric threshold is changing and why, and guardrails to prevent unintended harm to small-patient therapies.
If the change is modest and backed by impact assessment and phased implementation, a centrist is inclined to support it.
A mainstream conservative would likely oppose the bill as an additional expansion of federal price-setting authority into the pharmaceutical market, arguing it risks undermining incentives for private-sector innovation in biotech and rare-disease therapies.
They would view changing statutory thresholds to capture more orphan drugs for negotiation as government overreach that could reduce U.S. competitiveness and investment in life‑science research.
They might acknowledge an intent to limit 'gaming' but prefer market-based or targeted solutions instead.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone the bill is a narrow, easily described statutory tweak that protects a focused category (orphan drugs) and therefore can attract targeted stakeholder support. However, because it affects federal drug price negotiation — a high‑stakes, politically sensitive policy area with clear fiscal implications — it is less likely to advance as a freestanding bill. Its best path would be inclusion as a provision in larger, negotiated drug‑pricing or budget legislation; absent that vehicle or clear offsets, the standalone probability of enactment is modest.
The bill has not accumulated any surfaced votes yet.
Whether the threshold change is an appropriate way to stop 'gaming' versus an overbroad policy that threatens innovation.
On content alone the bill is a narrow, easily described statutory tweak that protects a focused category (orphan drugs) and therefore can a…
Relative to its intended legislative type, this bill is a narrowly targeted statutory amendment that identifies the specific provisions to change and sets an effective date. It is explicit in placement within existing l…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.